Bull & Bear

Bull and Bear

Verdict: Lean Long, Wait For Confirmation - Bull has the stronger long-horizon case (a measurable four-year, 460-bp adjusted operating margin walk through inflation, FX and integration stress, on a >90% recurring chronic-care base trading at a 35% peer discount), but Bear's forensic and event stack (adj-to-reported NI ratio doubling to 2.05x, trade receivables +25.1% on revenue +6.6%, the 3-Feb-2026 FDA Warning Letter on Unomedical, and a CEO/anchor/NED transition cluster) is real and lands as a single bundle at FY26 H1 in August 2026. The most decisive tension is whether the FY25 22.3% adjusted operating margin print is a clean step in a multi-year compounding curve or a working-capital-funded bonus-hurdle clear - the same number is being read two ways. The decisive evidence is observable, sits inside a 12-month window, and is largely binary, so the right institutional posture is to underwrite the thesis but require confirmation rather than chase the cycle-low multiple before the clouds resolve. The condition that flips the verdict to Lean Long is FY26 H1 adjusted operating margin >=23.0% with trade receivables back below $370M and the FDA letter closed without enforcement; failure on any one of those resets the debate to Avoid.

Bull Case

Bull target: $4.00/share (~305p at 1.30 GBP/USD) on 19x FY26E adj EPS of ~$0.205, cross-checked to ~16x EV/Adj EBITDA on FY26E ~$700M (halfway between CTEC's 9x and Coloplast's 16.5x). Timeline 12-18 months. Primary catalyst is FY26 H1 (Aug 2026) printing adj op margin >=23.0% alongside completion of the BMS amortisation roll-off. Disconfirming signal: FDA Unomedical Warning Letter escalates to a consent decree forcing OEM second-sourcing, OR 1H FY26 trade receivables stay above $400M while adj op margin prints below 22.5%.

Bear Case

Bear downside: 180p (~$2.30/share, ~$4.5B mkt cap, ~$5.85B EV) on adj P/E compression from 16.7x to 13x on stalled FY26 adj EPS of $0.18 if margin holds at 22.3-22.5% on tariff drag, AR reversal and AWC deceleration; cross-check 7.5x EV/Adj EBITDA on $640M FY26 EBITDA = 167p. Timeline 12-18 months through FY26 H1 (Aug 2026), FY26 prelim (Feb 2027), and FDA dialogue. Primary trigger: FY26 H1 adj op margin <=22.5% AND/OR AR > $400M AND/OR InnovaMatrix run-rate <$15M. Cover signal: FDA letter closed without enforcement AND AR reverts below $370M AND FY26 H1 adj op margin steps to >=23.0% - all three together.

The Real Debate

Verdict

Lean Long, Wait For Confirmation. Bull carries more weight on the long-horizon case: a four-year, 460-bp adjusted operating margin walk through inflation, FX, and M&A integration on a >90% recurring chronic-care base is a measured trajectory, not a hope, and the cycle-low multiple plus the BMS-spin-out amortisation roll-off offer a mechanical path to rerate even before any volume contribution. The most important tension is the quality of the 22.3% margin print itself - the same number Bull reads as the fourth step on a deliberate curve, Bear reads as a $1M bonus-hurdle clear funded by a 25.1% trade-receivables build and a ten-day DPO extension. Bear could still be right because the FDA Unomedical Warning Letter sits over the only franchise that meaningfully differentiates Convatec from Coloplast, the leadership transition is unusually deep (CEO death, anchor exit, NED departure, 32.96% remuneration vote against), and AWC's structural #4 position caps how much of the Coloplast gap can ever close from the largest franchise. The verdict flips to Lean Long if FY26 H1 (Aug 2026) prints adjusted operating margin >=23.0% with trade receivables back below $370M and the FDA letter closes without enforcement; failure on any one of those resets the debate toward Avoid. Until then, the cycle-low multiple is real but premature to chase.